SCHEMBL25188299

SCHEMBL25188299

COC(=O)c1cn(S(=O)(=O)c2cccnc2)c(-c2ccc(F)cc2F)c1OC

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.44
▸ TUBB4A P04350 1/20 0.39
▸ TUBB P07437 1/20 0.39
▸ TUBA3C P0DPH7 1/20 0.39
▸ TUBA1B P68363 1/20 0.39
▸ TUBA4A P68366 1/20 0.39
▸ TUBB4B P68371 1/20 0.39
▸ TUBB3 Q13509 1/20 0.39
▸ TUBB2A Q13885 1/20 0.39
▸ TUBB8 Q3ZCM7 1/20 0.39
▸ TUBA3E Q6PEY2 1/20 0.39
▸ TUBA1A Q71U36 1/20 0.39
▸ TUBA1C Q9BQE3 1/20 0.39
▸ TUBB6 Q9BUF5 1/20 0.39
▸ TUBB2B Q9BVA1 1/20 0.39
▸ TUBB1 Q9H4B7 1/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ PIK3CG P48736 1/20 0.39
▸ HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31019969 1.00 POLB (0.44) POLBTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL25199143 0.90 KMT2A (0.43) POLBKMT2AMEN1PIK3CGHTT
SCHEMBL31019961 0.90 KMT2A (0.43) POLBKMT2AMEN1PIK3CGHTT
SCHEMBL25187015 0.89 KMT2A (0.40) POLBTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL31019972 0.89 KMT2A (0.40) POLBTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL30963571 0.88 MEN1 (0.42) KMT2AMEN1ALPLTSHR
SCHEMBL19385605 0.88 MEN1 (0.42) KMT2AMEN1ALPLTSHR
SCHEMBL30287367 0.87 PTGS2 (0.38) POLBKMT2AMEN1ALPLTSHR
SCHEMBL28996387 0.87 PTGS2 (0.38) POLBKMT2AMEN1ALPLTSHR
SCHEMBL28996384 0.85 KMT2A (0.38) KMT2AMEN1ALPLKDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250051275-A1 PYRROLE DERIVATIVE OR PHARMACEUTICALLY OR SITOLOGICALLY ACCEPTABLE SALTS THEREOF, AND COMPOSITION FOR PREVENTION, AMELIORATION OR TREATMENT OF GASTROINTESTINAL DISORDERS COMPRISING SAME AS ACTIVE INGREDIENT HANA PHARM CO., LTD. (KR) 2025-02-13 — — US disclosed
EP-4434966-A1 PYRROLE DERIVATIVE OR PHARMACEUTICALLY OR SITOLOGICALLY ACCEPTABLE SALT THEREOF, AND COMPOSITION FOR PREVENTION, AMELIORATION OR TREATMENT OF GASTROINTESTINAL DISORDERS COMPRISING SAME AS ACTIVE INGREDIENT Hana Pharm. Co. Ltd. (KR) 2024-09-25 — — EP disclosed
WO-2023090942-A1 PYRROLE DERIVATIVE OR PHARMACEUTICALLY OR SITOLOGICALLY ACCEPTABLE SALT THEREOF, AND COMPOSITION FOR PREVENTION, AMELIORATION OR TREATMENT OF GASTROINTESTINAL DISORDERS COMPRISING SAME AS ACTIVE INGREDIENT 하나제약 주식회사 2023-05-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250051275-A1 PYRROLE DERIVATIVE OR PHARMACEUTICALLY OR SITOLOGICALLY ACCEPTABLE SALTS THEREOF, AND COMPOSITION FOR PREVENTION, AMELIORATION OR TREATMENT OF GASTROINTESTINAL DISORDERS COMPRISING SAME AS ACTIVE INGREDIENT STOM, SI, PGC POLB 3324/4885TUBB4A 4611/4885TUBB 4581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback